Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,

Abstract

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Org: University Hospitals Leuven, Leuven, Belgium, Vall d’Hebron University Hospital/VHIO, Department of Oncology, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Centre Singapore,

Abstract

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,

Abstract

A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.

Org: University Hospitals Leuven, Leuven, Belgium, Academic Centre for Nursing and Midwifery, Universitair Ziekenhuis Brussel, European Medicines Agency, Department of Public Health and Primary Care,

Abstract

Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).

Org: Assistance Publique - Hôpitaux de Paris (APHP), University Paris-Saclay, Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, Service de Chirurgie HPB Transplantation, Hopital Haut Leveque,

Abstract

BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.

Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,

Abstract

Role of social determinants burden on outcomes and survival for AYAs with cancer.

Org: University Hospitals Cleveland Medical Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, Angie Fowler Chair in Adolescent & Young Adult Cancer Research, Angie Fowler AYA Cancer Institute,

Abstract

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),

Abstract

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,

Abstract

Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.

Org: Nantes Université, CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, University Hospitals Leuven, Leuven Cancer Institute, and BGOG,

Abstract

StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Org: University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium, Oregon Health & Science University, Portland, OR, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, Germany,

Abstract

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Netherlands Cancer Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,

Abstract

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), University of Virginia, Charlottesville, VA, USA, University Hospitals Leuven, Leuven, Belgium, Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine,

Abstract

The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.

Org: Leiden University Medical Center, Institut de Cancérologie Gustave Roussy, London Regional Cancer Program Ontario, Tübingen University Hospital, Fondazione Policlinico Universitario A. Gemelli IRCCS,

Abstract

Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.

Org: Centre Léon Berard, UNIV Lyon-Université Claude Bernard Lyon 1, Genotypos M.S.A., Genotypos Science Labs, AGO Study Group & Ev. Kliniken Essen-Mitte,

Abstract

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

Org: Sorbonne University and Saint-Antoine Hospital, Mayo Clinic, Monash University School of Public Health and Preventive Medicine, Cardiff University School of Medicine, University of Pisa, Pisa, Italy,

Abstract

Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.

Org: AstraZeneca, University Hospitals Leuven, Leuven, Belgium, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Seoul National University College of Medicine, Christie Hospital NHS Foundation Trust and the University of Manchester,

Abstract

Serum soluble MAdCAM-1: A new biomarker for cancer immunotherapy.

Org: Gustave Roussy Cancer Campus, Centre Léon Bérard, Department of Medicine and Surgery, University of Parma, Parma, Italy, University of Parma, Medical Oncology Group,

Abstract

Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases.

Org: Laboratory of Experimental Oncology (LEO), Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Laboratory of Cell Stress & Immunity (CSI), Department of Cellular and Molecular Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.

Org: University Hospitals Leuven, Leuven, Belgium, VIB Center for Cancer Biology, University of Leuven, KU Leuven, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).

Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,

Abstract

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.

Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,

Abstract

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.

Org: Medical University of South Carolina Hollings Cancer Center, Institut Català d’Oncologia L’Hospitalet de Llobregat, Hospital Duran i Reynals, IDIBELL, Grupo Español de Investigación en Cáncer de Ovario (GEICO),

Abstract

Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.

Org: Laboratory of Experimental Oncology (LEO), Laboratory for Translational Cell and Tissue Research, Multidisciplinary Breast Center, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, University Hospitals Leuven, Leuven, Belgium,

Abstract

Safety analysis of lurbinectedin versus topotecan in elderly patients.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,

Abstract

“TO REGAIN ONE’S HEALTH” – PATIENTS’ PREFERENCES OF TREATMENT OUTCOMES IN EARLY RHEUMATOID ARTHRITIS – A QUALITATIVE STUDY

Org: Lund University, Skåne University Hospital, Lund University, RandD Spenshult, Department of Clinical Sciences, Surgery, Lund University, Section of Rheumatology,

Abstract

Are illness perception and coping style associated with patient delay?

Org: University Hospitals Leuven, Leuven, Belgium, KU Leuven, Department of Development and Regeneration, Leuven, Belgium,

Abstract

ACHIEVING THE TREATMENT TARGETS OF REMISSION OR LOW DISEASE ACTIVITY (LDA) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED QUALITY OF LIFE, FUNCTION AND PAIN

Org: Janssen-Cilag B.V, Tilburg, Netherlands, University Hospitals Leuven, Leuven, Belgium, Fondazione Policlinico Gemelli-IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy, Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, Janssen-Cilag B.V, Brussels, Belgium,

Abstract

Biologic dmards and psoriatic arthritis in europe in 2016/2017: characteristics of patients starting tnf-inhibitors or ustekinumab in the ongoing psabio observational cohort study

Org: Sorbonne Université, Paris, France, St. Paul (Agios Pavlos) Hospital, Thessaloniki, Greece, Janssen-Cilag B.V., Breda, Netherlands, University Hospitals Leuven, Leuven, Belgium, Fondazione Policlinico Gemelli-Catholic University of the Sacred Heart, Rome, Italy,